Dyadic, Medytox to develop COVID-19 vaccines against variants

By The Science Advisory Board staff writers

March 23, 2021 -- Dyadic International and South Korean biopharmaceutical firm Medytox have partnered to co-develop C1-enabled vaccines and boosters that will immunize against COVID-19 variants.

The partnership expands an existing agreement between the two companies that began last July and will confer exclusive license for South Korea and other Southeast Asian countries.

C1 vaccine technology is derived from a fungus gene expression platform and shows promise for the development of multivalent vaccines that can be used against COVID-19 variants; it does not require large-scale bioreactor facilities to be manufactured, according to the two firms.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.